A no-BS breakdown of the clinical trial data, what triple agonism means for research, and why the peptide community is losing its mind. Retatrutide (LY-3437943) represents a new class of triple agonist peptides targeting GLP-1, GIP, and glucagon receptors simultaneously. This research brief examines the Phase 3 clinical data comparing Retatrutide to Tirzepatide across multiple endpoints relevant to metabolic research.